Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
This would make it the third major incretin-based obesity drug to reach the market, following semaglutide (Wegovy) and tirzepatide (Zepbound), but the first to use the full triple-agonist mechanism
Kong Y, Li K, Fu T, Wan C, Zhang D, Song H, et al
Food and Drug Administration to sell versions of Novos GLP-1 injectible drugs while the branded medicines were in short supply
In the journey toward achieving a healthier weight, finding an effective and sustainable solution is often challenging
US$ 29.77
US$ 23.03
US$ 26.22
US$ 28.22
![Arceus (XY116) [XY: Black Star Promos] SPA Santuario de Ugin](https://cdn.shopify.com/s/files/1/0268/5285/1798/files/27ff2544-822b-4160-9779-8b5d34f54148.png?v=1755130157)